BridgeMD
[18F]Tetrafluoroborate PET/CT for the Detection of Differentiated Thyroid Cancer: A Phase II Imaging Study
EU CTIS ID: 2024-516025-30-00
What this study is testing
a) To determine the optimal time point acquisition of [18F]TFB PET/CT, b) to determine the value of [18F]TFB PET/CT for detection of (pre-operative) metastatic lymph node(s) in patients with differentiated thyroid cancer and c) to determine the value of [18F]TFB PET/CT for the estimation of radioiodine therapy response in patients with persistent and recurrent differentiated thyroid cancer.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Group 1: patients with newly diagnosed differentiated thyroid cancer and pathologically proven lymph node metastases thyroid cancer referred for surgical resection - Group 2: patients with differentiated thyroid cancer referred for 131I therapy - The patient has provided written informed consent authorization before participating in the study - The patient is ≥ 18 years old - The patient has an ECOG status grade 0-2
You likely can't join if
- - Patient is mentally or legally incapacitated - Patient is pregnant or lactating - Patient has been subjected to an excess of substrates of the sodium iodine symporter such as iodine (e.g. in the form of iodinated contrast agent) or perchlorate within the past 2 months. - Patient takes lithium - Patient takes amiodarone
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.